Pharma Resisting Efforts To Send Drug Pricing Savings To US Budget ‘Black Hole’ – Pfizer’s Bourla
Biopharma draws a line in the sand on drug pricing reform and offers to come to the table, but given the fracturing support for Rx legislation within the Democratic caucus, industry may not have as much need to negotiate with Congress. More detail on industry’s latest proposals for lowering costs may come in the second half.
You may also be interested in...
Pricing policies aimed at lowering Medicare Part B costs should be ‘relatively easy’ to accomplish but they wouldn’t be as effective in satisfying industry critics as reforms in Part D, securities analyst Geoffrey Porges says.
Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.
White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.